Cargando…
Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials
The results of our third trial on epicutaneous allergen-specific immunotherapy (EPIT) will be presented and discussed in the context of our previous trials. This monocentric, placebo-controlled, double-blind phase I/IIa trial included 98 patients with grass pollen rhinoconjunctivitis. Prior to the p...
Autores principales: | Senti, G, von Moos, S, Tay, F, Graf, N, Johansen, P, Kündig, T M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654258/ https://www.ncbi.nlm.nih.gov/pubmed/25704072 http://dx.doi.org/10.1111/all.12600 |
Ejemplares similares
-
Epicutaneous Immunotherapy for Aeroallergen and Food Allergy
por: Senti, Gabriela, et al.
Publicado: (2013) -
Innovative Systems to Deliver Allergen Powder for Epicutaneous Immunotherapy
por: Wang, Yensheng, et al.
Publicado: (2021) -
Heat‐labile Escherichia coli toxin enhances the induction of allergen‐specific IgG antibodies in epicutaneous patch vaccination
por: Cabauatan, C. R., et al.
Publicado: (2016) -
Is The Allergen Really Needed in Allergy Immunotherapy?
por: Kündig, Thomas M., et al.
Publicado: (2014) -
Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities
por: Davis, Carla M., et al.
Publicado: (2022)